Anti-CD123 Monoclonal Antibody CSL362

A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, anti-CD123 monoclonal antibody CSL362 binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. (NCI Thesaurus)

YOU MAY ALSO LIKE

Anti-CD123 Monoclonal Antibody CSL360

A chimeric IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain) with potential antineoplastic activity. Derived from mouse monoclonal antibody 7G3, anti-CD123…

anti-CCR2 monoclonal antibody MLN1202

A substance being studied as a treatment for atherosclerosis (a build-up of fat in the arteries). It is also being studied in…

Anti-CA6-DM4 Immunoconjugate SAR566658

An immunoconjugate consisting of a humanized monoclonal antibody against the tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4, with potential…

Anti-c-MET Monoclonal Antibody LY2875358

A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Anti-c-MET monoclonal antibody…

Anti-c-Met Monoclonal Antibody ABT-700

A monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody ABT-700 binds…

Anti-c-fms Monoclonal Antibody AMG 820

A fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (or CSFR1), with potential antineoplastic activity. Upon…